


# Supplementary Material



**Fig. 1.** Patient flow through enrolment, allocation, follow-up and analysis

**Table 1.** Psychotropic Medication

	<b>DBT-PTSD Percentage (n)</b>	<b>TAU-WL Percentage (n)</b>	<b>Fisher's Exact Test p-value</b>
<b>Psychotropic medication at randomisation (t1)</b>			
Any psychotropic medication	83.4% (n=30)	89.5% (n=34)	0.51
Antipsychotics	41.7% (n=15)	44.7% (n=17)	0.82
Antidepressants	69.4% (n=25)	71.1% (n=27)	1.00
Mood Stabilizer	19.4% (n=7)	18.4% (n=7)	1.00
Other psychotropic medication	36.1% (n=13)	42.1% (n=16)	0.64
<b>Psychotropic medication 3 months after randomisation (t2)</b>			
Any psychotropic medication	82.9% (n=29)	87.1% (n=27)	0.74
Antipsychotics	31.4% (n=11)	51.6% (n=16)	0.13
Antidepressants	74.3% (n=26)	67.7% (n=21)	0.60
Mood Stabilizer	20.0% (n=7)	19.4% (n=6)	1.00
Other psychotropic medication	42.9% (n=15)	45.2% (n=14)	1.00
<b>Change in psychotropic medication</b>			
Change in any psychotropic medication	77.8% (n=28)	57.9% (n=22)	0.09
Change in Antipsychotics	40.0% (n=14)	25.8% (n=8)	0.30
Change in Antidepressants	54.3% (n=19)	38.7% (n=12)	0.23
Change in Mood Stabilizer	8.6% (n=3)	9.7% (n=3)	1.00
Change in other psychotropic medication	45.7% (n=16)	25.8% (n=8)	0.13

**Table 2. HLM Analysis**

	Whole sample; n=74		≥ 5 BPD criteria; n=33		< 5 BPD criteria; n=41	
Measure	*Group x time interaction (SD)	p-value	*Group x time interaction (SD)	p-value	*Group x time interaction (SD)	p-value
<b>Clinician-Administered PTSD Scale</b>	-1.138 (0.195)	p<0.001	-1.510 (0.249)	p<0.001	-0.496 (0.234)	p=0.038
<b>Posttraumatic Diagnostic Scale</b>	-0.021 (0.006)	p<0.001	-0.026 (0.009)	p=0.007	-0.016 (0.008)	p=0.043
<b>Global Assessment of Functioning</b>	0.503 (0.094)	p<0.001	0.485 (0.149)	p=0.002	0.590 (0.119)	p<0.001
<b>Borderline Symptom List</b>	-0.006 (0.006)	p=0.334	-0.005 (0.008)	p=0.559	-0.008 (0.009)	p=0.391
<b>Dissociative Experiences Scale (FDS-20)</b>	-0.139 (0.128)	p=0.278	-0.030 (0.177)	p=0.867	-0.228 (0.179)	p=0.208
<b>Beck Depression Inventory II</b>	-0.223 (0.089)	p<0.0135	-1.188 (0.133)	p=0.164	-0.346 (0.126)	p=0.008
<b>Symptom Checklist-90-Revised</b>	-0.002 (0.005)	p=0.672	-0.009 (0.009)	p=0.322	0.004 (0.007)	p=0.557
<b>IPDE-BPD criteria</b>	-0.012 (0.006)	p=0.072	-0.018 (0.009)	p=0.049	-0.007 (0.008)	p=0.358

\* Regression parameter modelling the group x time interaction, based on HLM analysis

**Table 3.** Treatment Results: Secondary outcome data (available data)

	Whole sample; n=74		≥ 5 BPD criteria; n=33		< 5 BPD criteria; n=41	
Measurement	DBT-PTSD (n=36)	TAU-WL (n=38)	DBT-PTSD (n=17)	TAU-WL (n=16)	DBT-PTSD (n=19)	TAU-WL (n=22)
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
<b>Global Assessment of Functioning</b>						
Pretreatment	41.50 (4.50)	42.79 (7.19)	41.88 (4.34)	39.44 (6.31)	41.16 (4.72)	45.23 (6.91)
12 weeks (discharge)	50.56 (8.00)	43.82 (7.86)	48.93 (7.49)	41.08 (7.37)	52.00 (8.34)	45.60 (7.83)
18 weeks (follow-up)	53.41 (7.31)	42.90 (8.46)	51.62 (7.23)	38.00 (6.16)	55.07 (7.26)	46.44 (8.24)
24 weeks (follow-up)	51.69 (10.55)	43.22 (8.34)	50.79 (11.97)	39.33 (5.53)	52.53 (9.38)	45.55 (8.96)
Hedges' g (between groups; t1-t4)	1.01		0.81		1.14	
<b>Borderline Symptom List</b>						
Pretreatment	2.18 (0.69)	2.27 (0.67)	2.13 (0.69)	2.56 (0.62)	2.22 (0.71)	2.04 (0.63)
12 weeks (discharge)	1.60 (0.77)	2.17 (0.70)	1.79 (0.76)	2.35 (0.82)	1.41 (0.76)	1.94 (0.66)
18 weeks (follow-up)	1.66 (0.69)	2.03 (0.73)	1.68 (0.71)	2.22 (0.87)	1.41 (0.70)	1.87 (0.58)
24 weeks (follow-up)	1.74 (0.75)	2.03 (0.74)	1.90 (0.61)	2.34 (0.60)	1.54 (0.70)	1.72 (0.78)
Hedges' g (between groups; t1-t4)	0.38		0.10		0.59	
<b>Dissociative Experiences Scale (FDS-20)</b>						
Pretreatment	31.39 (16.78)	26.90 (17.05)	33.99 (14.98)	34.21 (18.74)	28.92 (18.41)	21.34 (13.60)
12 weeks (discharge)	20.34 (13.88)	24.28 (15.10)	23.60 (15.08)	29.67 (16.62)	17.26 (12.31)	20.87 (13.40)
18 weeks (follow-up)	20.99 (13.17)	24.35 (18.15)	26.86 (14.39)	29.73 (20.85)	14.63 (8.22)	20.66 (15.58)
24 weeks (follow-up)	21.38 (16.84)	22.36 (16.50)	25.50 (19.45)	27.80 (16.03)	17.56 (13.60)	18.55 (15.94)
Hedges' g (between groups; t1-t4)	0.30		0.14		0.38	
<b>Beck Depression Inventory II</b>						
Pretreatment	38.00 (9.75)	39.53 (9.13)	37.18 (11.43)	41.19 (8.64)	38.74 (8.21)	38.32 (9.48)
12 weeks (discharge)	26.03 (11.42)	39.88 (11.14)	28.25 (11.63)	41.75 (9.31)	24.06 (11.19)	38.95 (11.52)
18 weeks (follow-up)	29.39 (9.06)	40.19 (10.69)	32.46 (8.19)	41.75 (11.62)	26.31 (9.12)	39.21 (9.22)
24 weeks (follow-up)	30.67 (11.96)	36.71 (12.86)	33.46 (12.32)	39.38 (12.50)	28.07 (11.45)	35.30 (12.87)
Hedges' g (between groups; t1-t4)	0.49		0.22		0.75	
<b>Symptom Checklist-90-Revised</b>						
Pretreatment	1.90 (0.66)	2.01 (0.58)	1.80 (0.66)	2.05 (0.56)	1.99 (0.67)	1.97 (0.59)
12 weeks (discharge)	1.37 (0.65)	1.91 (0.65)	1.45 (0.67)	1.97 (0.66)	1.30 (0.62)	1.87 (0.60)
18 weeks (follow-up)	1.39 (0.58)	1.79 (0.70)	1.34 (0.61)	1.88 (0.81)	1.30 (0.56)	1.74 (0.57)
24 weeks (follow-up)	1.45 (0.64)	1.68 (0.69)	1.44 (0.63)	1.91 (0.59)	1.40 (0.64)	1.52 (0.71)
Hedges' g (between groups; t1-t4)	0.28		0.32		0.24	
<b>IPDE-BPD criteria</b>						
Pretreatment	4.22 (1.64)	4.00 (2.03)	5.59 (0.80)	5.94 (1.06)	3.00 (1.16)	2.59 (1.22)
12 weeks (discharge)	2.41 (1.80)	3.52 (2.08)	2.93 (2.09)	4.46 (1.81)	1.94 (1.39)	2.90 (2.05)
18 weeks (follow-up)	2.81 (1.42)	3.44 (2.40)	3.54 (1.33)	4.62 (2.10)	2.14 (1.17)	2.63 (2.29)
24 weeks (follow-up)	2.41 (1.69)	3.10 (2.22)	2.54 (1.94)	4.64 (2.50)	2.29 (1.49)	2.21 (1.48)
Hedges' g (between groups; t1-t4)	0.48		0.67		0.15	

**Table 4.** Correlation between Change in Medication and Primary Outcome Variables in all Participants

	<b>Change in Antipsychotics r (p-value)</b>	<b>Change in Antidepressants r (p-value)</b>	<b>Change in Mood Stabilizer r (p-value)</b>	<b>Change in any other psychotropic medication r (p-value)</b>	<b>Change in psychotropic medication r (p-value)</b>
<b>CAPS</b>	-0.02 (0.91)	0.01 (0.94)	-0.07 (0.57)	0.07 (0.55)	-0.03 (0.80)
<b>PDS</b>	0.05 (0.72)	0.09 (0.55)	-0.11 (0.46)	0.26 (0.07)	0.20 (0.15)

Note: Point-biserial correlation coefficient (r) and corresponding p-value